<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04776915</url>
  </required_header>
  <id_info>
    <org_study_id>2020-18/17</org_study_id>
    <nct_id>NCT04776915</nct_id>
  </id_info>
  <brief_title>Congenital Uterine Anomalies &amp; Pregnancy in Polycystic Ovarian Syndrome</brief_title>
  <acronym>CONUTA&amp;PPCOS</acronym>
  <official_title>Investigation of the Effect of Serum Androgen and Anti-Mullerian Hormone Levels on the Frequency of Müllerian Anomalies and Pregnancy Outcomes in Patients With Polycystic Ovarian Syndrome Undergoing Invitro Fertilization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uludag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uludag University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective research in which patients who applied to UUTF Gynecology and Obstetrics ART&#xD;
      center for the treatment of infertility (inability to conceive despite one year of&#xD;
      unprotected sexual intercourse), who will undergo IVF due to PCOS and unexplained infertility&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As of 01/10/2020, IVF cycles of patients with PCOS (n = 105) and unexplained infertility (n =&#xD;
      105) who have applied to Bursa Uludag University Gynecology and Obstetrics Department,&#xD;
      Reproductive Treatments Center, will be included in the study. Demographic data of all&#xD;
      patients (age, BMI, smoking), presence of hyperandrogenism findings such as systemic&#xD;
      diseases, hirsutism, alopecia, FSH, LH, LH/FSH ratio, estradiol levels, pregestational serum&#xD;
      AMH levels, uterine anomalies detected by transvaginal USG or hysterosalpingography,&#xD;
      controlled ovarian hyperstimulation protocols and doses; Besides, DHEA-S, Free Testosterone,&#xD;
      17-OH Progesterone levels will be recorded in patients diagnosed with PCOS. All these data&#xD;
      are routine laboratory and imaging parameters of patients who underwent in vitro&#xD;
      fertilization in our UYTE center. Pregnancy results of the patients (biochemical pregnancy,&#xD;
      anembryonic pregnancy, abortion, clinical pregnancy, live birth), perinatal results and&#xD;
      complications during clinical pregnancy, delivery ways, and newborn APGAR scores will be&#xD;
      recorded. Results will be compared with patients in the control group diagnosed with&#xD;
      unexplained infertility.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of Mullerian Abnormality</measure>
    <time_frame>One year</time_frame>
    <description>ESHRE&amp;ESGE uterine abnormality classification</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Mullerian Anomaly of Uterus, Nec</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <description>Infertile patients due to polycystic ovarian syndrome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>Infertile patients due to unexplained infertility</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Ultrasound and Hysterosalpingography</intervention_name>
    <description>Ultrasound and Hysterosalpingography</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Infertile Patients who undergo IVF&amp;ICSI treatment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Being in the age range of 20-40&#xD;
&#xD;
          -  Need for an assisted reproductive method due to PCOS or unexplained infertility&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt;20 years or &gt;40 years&#xD;
&#xD;
          -  Detecting a cause for infertility other than PCOS&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Özge Albayrak, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bursa Uludag University School of Medicine ART Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gürkan Uncu, Prof.</last_name>
    <phone>+902242952541</phone>
    <email>guncu@gurkanuncu.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kiper Aslan, M.D.</last_name>
    <phone>+902242952541</phone>
    <email>kiperaslan@yahoo.com.tr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uludag University ART Center</name>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gürkan Uncu, Prof.</last_name>
      <phone>02242952541</phone>
      <email>guncu@gurkanuncu.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2021</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Uludag University</investigator_affiliation>
    <investigator_full_name>GÜRKAN UNCU,PROF. MD</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>mullerian anomaly, PCOS, antimullerian hormone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

